Single or Double Induction with 7+3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DAUNODouble Trial by the Study Alliance Leukemia

Academic Background Acute Myeloid Leukemia (AML) is a malignant blood disorder, with the core of its treatment being induction chemotherapy, typically involving a combination of cytarabine and anthracyclines (such as daunorubicin). Although this treatment regimen has been in use since the 1980s, questions regarding the optimal dose of daunorubicin ...

A Prospective Study of Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: The Keystone-001 Trial

Background and Research Motivation Esophageal Squamous Cell Carcinoma (ESCC) is a highly aggressive cancer, especially in locally advanced stages. Traditional neoadjuvant chemoradiotherapy (NCRT) is the standard treatment method for this type of cancer. Despite its significant therapeutic effects, local recurrence and distant metastasis rates remai...